Keelan Z. Guiley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Keelan Z. Guiley has a total of 156 co-authors. Here are the top co-authors by number of shared publications:
- Kevan M. Shokat
Department of Cellular and Molecular Pharmacology, Howard Hughes Medical Institute, University of California, San Francisco, USA
38 shared publications - Allison M. Kehlmann
Mass General Brigham 2 Boston, MA
3 shared publications - Alvin A. Morales-Giron
Massachusetts General Hospital Cancer Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts
3 shared publications - Andreas Varkaris
Massachusetts General Hospital Cancer Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts
3 shared publications - Ankit Singh
Massachusetts General Hospital Cancer Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts
3 shared publications - Aparna Raj Parikh
Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA
3 shared publications
Latest Publications
- Open Access
Discovery of molecular glues for modulating MHC presentation of cancer neo-antigens
Antigen presentation by MHC class I molecules is essential for cancer immunosurveillance, but many cancer-specific antigens fail to form complexes with Class I MHC and are poorly presented on the cell surface. In this study, we present a chemical strategy to overcome this limitation by identifying peptide MHC glues (PMGs) that promote the formation of peptide-MHC complexes with otherwise unpresentable cancer antigens. Crystal structures of these complexes show that our compounds stabilize antigen-MHC binding by making simultaneous interactions with the MHC protein and the antigen peptides. These findings reveal a new approach for chemically rewiring Class I MHC antigen presentation and accessing rare cancer antigens for therapeutic targeting.
Open AccessDiscovery of molecular glues for modulating MHC presentation of cancer neo-antigens
Antigen presentation by MHC class I molecules is essential for cancer immunosurveillance, but many cancer-specific antigens fail to form complexes with Class I MHC and are poorly presented on the cell surface. In this study, we present a chemical strategy to overcome this limitation by identifying peptide MHC glues (PMGs) that promote the formation of peptide-MHC complexes with otherwise unpresentable cancer antigens. Crystal structures of these complexes show that our compounds stabilize antigen-MHC binding by making simultaneous interactions with the MHC protein and the antigen peptides. These findings reveal a new approach for chemically rewiring Class I MHC antigen presentation and accessing rare cancer antigens for therapeutic targeting.
- Open Access
Chemical Genetic Targeting of the LRRK2 GTPase Domain
Genetic variants throughout the multi-domain protein leucine-rich repeat kinase 2 ( LRRK2) gene are the most common cause of autosomal dominant Parkinson’s disease, and the most prevalent Parkinson’s-associated LRRK2 variants enhance kinase activity. Hence, the kinase domain has been extensively targeted for therapeutic development. However, clinical progression of LRRK2 kinase inhibitors has been limited by on-target peripheral toxicities linked to strong kinase suppression, raising the question of whether targeting LRRK2 kinase activity through other means could offer a more tunable therapeutic window. LRRK2 is one of two proteins in the human proteome that possess a Roc-COR GTPase domain in tandem with a kinase domain, and the GTPase domain has been shown to intramolecularly regulate kinase output. Here, we ask whether the Roc-COR GTPase can be targeted as an alternative approach to downregulate kinase activity. We utilize a chemical genetic approach to sensitize LRRK2 to existing GTPase inhibitors and show that pharmacologically engaging the Roc-COR GTPase domain in cells decreases but does not fully inhibit LRRK2-mediated Rab10 T73 phosphorylation. This study lays the groundwork for future efforts directed at the development of pharmacological inhibitors for the LRRK2 GTPase, providing an alternative approach for therapies targeting LRRK2-driven Parkinson’s disease.
Open AccessChemical Genetic Targeting of the LRRK2 GTPase Domain
Genetic variants throughout the multi-domain protein leucine-rich repeat kinase 2 ( LRRK2) gene are the most common cause of autosomal dominant Parkinson’s disease, and the most prevalent Parkinson’s-associated LRRK2 variants enhance kinase activity. Hence, the kinase domain has been extensively targeted for therapeutic development. However, clinical progression of LRRK2 kinase inhibitors has been limited by on-target peripheral toxicities linked to strong kinase suppression, raising the question of whether targeting LRRK2 kinase activity through other means could offer a more tunable therapeutic window. LRRK2 is one of two proteins in the human proteome that possess a Roc-COR GTPase domain in tandem with a kinase domain, and the GTPase domain has been shown to intramolecularly regulate kinase output. Here, we ask whether the Roc-COR GTPase can be targeted as an alternative approach to downregulate kinase activity. We utilize a chemical genetic approach to sensitize LRRK2 to existing GTPase inhibitors and show that pharmacologically engaging the Roc-COR GTPase domain in cells decreases but does not fully inhibit LRRK2-mediated Rab10 T73 phosphorylation. This study lays the groundwork for future efforts directed at the development of pharmacological inhibitors for the LRRK2 GTPase, providing an alternative approach for therapies targeting LRRK2-driven Parkinson’s disease.
- Top Cited Papers
- 27 August 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 393 (6814)
Autism mutations rewire protein interaction networks to drive neurodevelopmental pathology
Systematic mapping of protein-protein interaction (PPI) networks and determining how causal mutations rewire them in autism spectrum disorder (ASD) provide a powerful framework for uncovering disease mechanisms and therapeutic opportunities. Using affinity purification–mass spectrometry, we systematically mapped PPIs for 100 high-confidence ASD genes, uncovering more than 1800 interactions. By assessing the impact of pathogenic missense mutations, leveraging AlphaFold, and validating key findings in human-derived model systems, we identified marked convergence onto shared protein complexes in the wild-type state and convergent PPI rewiring driven by independent mutations. For example, distinct patient-derived variants in FOXP1 disrupt its interactions with FOXP4, leading to changes in cortical neurogenesis and neural activity in brain organoids. Overall, these findings link genetic variation to protein networks and convergent neurodevelopmental dysfunction in ASD.
- 27 August 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 393 (6814)
Top Cited PapersAutism mutations rewire protein interaction networks to drive neurodevelopmental pathology
Systematic mapping of protein-protein interaction (PPI) networks and determining how causal mutations rewire them in autism spectrum disorder (ASD) provide a powerful framework for uncovering disease mechanisms and therapeutic opportunities. Using affinity purification–mass spectrometry, we systematically mapped PPIs for 100 high-confidence ASD genes, uncovering more than 1800 interactions. By assessing the impact of pathogenic missense mutations, leveraging AlphaFold, and validating key findings in human-derived model systems, we identified marked convergence onto shared protein complexes in the wild-type state and convergent PPI rewiring driven by independent mutations. For example, distinct patient-derived variants in FOXP1 disrupt its interactions with FOXP4, leading to changes in cortical neurogenesis and neural activity in brain organoids. Overall, these findings link genetic variation to protein networks and convergent neurodevelopmental dysfunction in ASD.
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Data from Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators
The tumor-suppressor TP53 is the most frequently altered gene in cancer, and the Y220C hotspot, found in 1.8% of TP53-mutant tumors, creates a druggable cavity that destabilizes p53. Rezatapopt, a first-in-class, orally bioavailable reactivator of Y220C-mutant p53, has demonstrated promising initial efficacy in the phase 1/2 PYNNACLE trial. We report the first clinical mechanisms of resistance to this therapeutic class. Profiling of circulating tumor DNA, tumor biopsies, and rapid autopsy specimens upon rezatapopt progression revealed multiple heterogenous secondary TP53 alterations in cis with Y220C, including (i) DNA-binding domain mutations or frameshift/nonsense mutations that abolish transcriptional activity and (ii) mutations within the Y220C-binding surface predicted to hinder drug binding. Functional modeling confirmed that these double mutants eliminate p53 reactivation and target gene induction by rezatapopt. These findings establish a molecular framework for resistance to p53 Y220C reactivators and inform strategies to overcome resistance with next-generation agents.Significance:This study illustrates how pan-cancer resistance to Y220C-mutant p53 reactivators emerges in patients, indicating that on-target acquired alterations can represent a major mechanism of clinical resistance. These insights establish a molecular basis for therapeutic failure and provide a framework for developing next-generation agents to overcome resistance.See related commentary by Liu and Gu, p. 620
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators
The tumor-suppressor TP53 is the most frequently altered gene in cancer, and the Y220C hotspot, found in 1.8% of TP53-mutant tumors, creates a druggable cavity that destabilizes p53. Rezatapopt, a first-in-class, orally bioavailable reactivator of Y220C-mutant p53, has demonstrated promising initial efficacy in the phase 1/2 PYNNACLE trial. We report the first clinical mechanisms of resistance to this therapeutic class. Profiling of circulating tumor DNA, tumor biopsies, and rapid autopsy specimens upon rezatapopt progression revealed multiple heterogenous secondary TP53 alterations in cis with Y220C, including (i) DNA-binding domain mutations or frameshift/nonsense mutations that abolish transcriptional activity and (ii) mutations within the Y220C-binding surface predicted to hinder drug binding. Functional modeling confirmed that these double mutants eliminate p53 reactivation and target gene induction by rezatapopt. These findings establish a molecular framework for resistance to p53 Y220C reactivators and inform strategies to overcome resistance with next-generation agents.Significance:This study illustrates how pan-cancer resistance to Y220C-mutant p53 reactivators emerges in patients, indicating that on-target acquired alterations can represent a major mechanism of clinical resistance. These insights establish a molecular basis for therapeutic failure and provide a framework for developing next-generation agents to overcome resistance.See related commentary by Liu and Gu, p. 620
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S6 from Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators
Supplementary Figure S1|List of p53 alterations detected in patient 1 at disease progression. Supplementary Figure S2|Mutations surrounding the Y220C crevice were not present before treatment with rezatapopt. Supplementary Figure S3|Acquired p53 alterations render cells insensitive to rezatapopt treatment. Supplementary Figure S4|Acquired p53 alterations render HNSCC cells insensitive to rezatapopt treatment. Supplementary Figure S5|Not all acquired mutations in the Y220C crevice result in p53 loss-offunction. Supplementary Figure S6|Alterations affecting P152 invariably led to resistance to rezatapopt, while some substitutions may retain partial p53 functionality.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S6 from Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators
Supplementary Figure S1|List of p53 alterations detected in patient 1 at disease progression. Supplementary Figure S2|Mutations surrounding the Y220C crevice were not present before treatment with rezatapopt. Supplementary Figure S3|Acquired p53 alterations render cells insensitive to rezatapopt treatment. Supplementary Figure S4|Acquired p53 alterations render HNSCC cells insensitive to rezatapopt treatment. Supplementary Figure S5|Not all acquired mutations in the Y220C crevice result in p53 loss-offunction. Supplementary Figure S6|Alterations affecting P152 invariably led to resistance to rezatapopt, while some substitutions may retain partial p53 functionality.
- Open Access
- 8 January 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (4) , 677-685
Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators
The tumor-suppressor TP53 is the most frequently altered gene in cancer, and the Y220C hotspot, found in 1.8% of TP53-mutant tumors, creates a druggable cavity that destabilizes p53. Rezatapopt, a first-in-class, orally bioavailable reactivator of Y220C-mutant p53, has demonstrated promising initial efficacy in the phase 1/2 PYNNACLE trial. We report the first clinical mechanisms of resistance to this therapeutic class. Profiling of circulating tumor DNA, tumor biopsies, and rapid autopsy specimens upon rezatapopt progression revealed multiple heterogenous secondary TP53 alterations in cis with Y220C, including (i) DNA-binding domain mutations or frameshift/nonsense mutations that abolish transcriptional activity and (ii) mutations within the Y220C-binding surface predicted to hinder drug binding. Functional modeling confirmed that these double mutants eliminate p53 reactivation and target gene induction by rezatapopt. These findings establish a molecular framework for resistance to p53 Y220C reactivators and inform strategies to overcome resistance with next-generation agents. Significance: This study illustrates how pan-cancer resistance to Y220C-mutant p53 reactivators emerges in patients, indicating that on-target acquired alterations can represent a major mechanism of clinical resistance. These insights establish a molecular basis for therapeutic failure and provide a framework for developing next-generation agents to overcome resistance. See related commentary by Liu and Gu, p. 620
- 8 January 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (4) , 677-685
Open AccessAcquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators
The tumor-suppressor TP53 is the most frequently altered gene in cancer, and the Y220C hotspot, found in 1.8% of TP53-mutant tumors, creates a druggable cavity that destabilizes p53. Rezatapopt, a first-in-class, orally bioavailable reactivator of Y220C-mutant p53, has demonstrated promising initial efficacy in the phase 1/2 PYNNACLE trial. We report the first clinical mechanisms of resistance to this therapeutic class. Profiling of circulating tumor DNA, tumor biopsies, and rapid autopsy specimens upon rezatapopt progression revealed multiple heterogenous secondary TP53 alterations in cis with Y220C, including (i) DNA-binding domain mutations or frameshift/nonsense mutations that abolish transcriptional activity and (ii) mutations within the Y220C-binding surface predicted to hinder drug binding. Functional modeling confirmed that these double mutants eliminate p53 reactivation and target gene induction by rezatapopt. These findings establish a molecular framework for resistance to p53 Y220C reactivators and inform strategies to overcome resistance with next-generation agents. Significance: This study illustrates how pan-cancer resistance to Y220C-mutant p53 reactivators emerges in patients, indicating that on-target acquired alterations can represent a major mechanism of clinical resistance. These insights establish a molecular basis for therapeutic failure and provide a framework for developing next-generation agents to overcome resistance. See related commentary by Liu and Gu, p. 620
- Open Access
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from A Small Molecule Reacts with the p53 Somatic Mutant Y220C to Rescue Wild-type Thermal Stability
Supplementary Figure S2: Differential scanning fluorimetry (A) Carbazole series plot of average values from differential scanning fluorimetry. (B) Indole series plot of average values from differential scanning fluorimetry. (C) Azaindole series plot of average values from differential scanning fluorimetry. (D) p53 Y220C-CL D228A DMSO or KG11 adduct plot of average values from differential scanning fluorimetry.
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from A Small Molecule Reacts with the p53 Somatic Mutant Y220C to Rescue Wild-type Thermal Stability
Supplementary Figure S2: Differential scanning fluorimetry (A) Carbazole series plot of average values from differential scanning fluorimetry. (B) Indole series plot of average values from differential scanning fluorimetry. (C) Azaindole series plot of average values from differential scanning fluorimetry. (D) p53 Y220C-CL D228A DMSO or KG11 adduct plot of average values from differential scanning fluorimetry.
- Open Access
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from A Small Molecule Reacts with the p53 Somatic Mutant Y220C to Rescue Wild-type Thermal Stability
Supplementary Figure S5: CDKN1A EMSA gels and intensity plots (A) EMSA for p53 WT-CL. (B) EMSA for p53 Y220C-CL. (C) EMSA for p53 Y220C-CL complexed with KG13. (D) EMSA for p53 R273C-CL. (E) Upper band intensities plotted for each protein construct. (F) Upper band intensities plotted for p53 R273C-CL.
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from A Small Molecule Reacts with the p53 Somatic Mutant Y220C to Rescue Wild-type Thermal Stability
Supplementary Figure S5: CDKN1A EMSA gels and intensity plots (A) EMSA for p53 WT-CL. (B) EMSA for p53 Y220C-CL. (C) EMSA for p53 Y220C-CL complexed with KG13. (D) EMSA for p53 R273C-CL. (E) Upper band intensities plotted for each protein construct. (F) Upper band intensities plotted for p53 R273C-CL.
- Open Access
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from A Small Molecule Reacts with the p53 Somatic Mutant Y220C to Rescue Wild-type Thermal Stability
Supplementary Figure S6: Western blots and for 28°C IP and CETSA (A) H1299 cells stably expressing p53 Y220C or p53 R273C were transferred from 37°C to 28°C and p21/MDM2 levels were monitored by western blot at the indicated time points. (B) U2OS cells stably expressing p53 Y220C or parent were transferred to a 28°C incubator and p21/MDM2 levels were observed by western blot at the indicated time points. (C) Extracts from H1299 cells expressing p53 Y220C incubated at 37°C or 28°C for 24 hr were immunoprecipitated with the WT conformation antibody Pab1620. (D) CETSA western blot for p53 Y220C DMSO. (E) CETSA western blot for p53 Y220C treated with 100 μM KG13 for 1 hr. (F) CETSA western blot for p53 WT DMSO.
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from A Small Molecule Reacts with the p53 Somatic Mutant Y220C to Rescue Wild-type Thermal Stability
Supplementary Figure S6: Western blots and for 28°C IP and CETSA (A) H1299 cells stably expressing p53 Y220C or p53 R273C were transferred from 37°C to 28°C and p21/MDM2 levels were monitored by western blot at the indicated time points. (B) U2OS cells stably expressing p53 Y220C or parent were transferred to a 28°C incubator and p21/MDM2 levels were observed by western blot at the indicated time points. (C) Extracts from H1299 cells expressing p53 Y220C incubated at 37°C or 28°C for 24 hr were immunoprecipitated with the WT conformation antibody Pab1620. (D) CETSA western blot for p53 Y220C DMSO. (E) CETSA western blot for p53 Y220C treated with 100 μM KG13 for 1 hr. (F) CETSA western blot for p53 WT DMSO.
- Open Access
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from A Small Molecule Reacts with the p53 Somatic Mutant Y220C to Rescue Wild-type Thermal Stability
Azaindole compounds stabilized p53 Y220C to WT levels. A, Chemical structures of the azaindole series. B, p53 Y220C-CL was fully labeled by the compounds and purified by size-exclusion chromatography, and its thermal stability was analyzed by differential scanning fluorimetry. The difference in Tm relative to unliganded p53 Y220C-CL is displayed. C, Crystal structure of p53 Y220C-CL bound to KG13 at 1.7 Å resolution. D, 1 μmol/L of p53 Y220C-CL or p53 Y220C-CL D228A was incubated with 10 μmol/L compound at 4°C for 24 hours. Adduct formation was analyzed by LC/MS.
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from A Small Molecule Reacts with the p53 Somatic Mutant Y220C to Rescue Wild-type Thermal Stability
Azaindole compounds stabilized p53 Y220C to WT levels. A, Chemical structures of the azaindole series. B, p53 Y220C-CL was fully labeled by the compounds and purified by size-exclusion chromatography, and its thermal stability was analyzed by differential scanning fluorimetry. The difference in Tm relative to unliganded p53 Y220C-CL is displayed. C, Crystal structure of p53 Y220C-CL bound to KG13 at 1.7 Å resolution. D, 1 μmol/L of p53 Y220C-CL or p53 Y220C-CL D228A was incubated with 10 μmol/L compound at 4°C for 24 hours. Adduct formation was analyzed by LC/MS.